19.2 Medication Education, Informed Consent & Informed Refusal
Key Takeaways
- The two highest-rated education activities in the 2025 practice analysis both concern medication information: intended effects and adverse events (index 11.05) and risks, benefits and outcomes enabling informed consent and refusal (index 10.43).
- Informed consent requires disclosure of the nature of the treatment, risks and benefits, reasonable alternatives including no treatment, and confirmation that the patient has decisional capacity and is acting voluntarily.
- Informed refusal requires the same disclosure process plus documentation of the specific consequences explained and the patient's stated reasons.
- Patients on buprenorphine or methadone must be taught that opioid tolerance falls rapidly after discontinuation, making overdose risk after a lapse far higher than before treatment.
- Off-label prescribing requires explicit disclosure that the agent lacks FDA approval for the indication, along with the magnitude of expected benefit and the alternatives.
19.2 Medication Education, Informed Consent & Informed Refusal
Quick Answer: The two highest-rated education activities in the ANCB practice analysis are both about medication: "provides healthcare consumers with information about intended effects and potential adverse events of proposed prescriptive treatments" (index 11.05) and "provides information on the risks, benefits, and outcomes of healthcare regimens to allow informed decision-making by the consumer, including informed consent and refusal" (index 10.43). Valid consent requires nature of treatment, risks, benefits, reasonable alternatives including no treatment, decisional capacity and voluntariness. Informed refusal requires the same process plus documentation of the specific consequences explained.
1. The Content of Medication Teaching
For every medication the APRN prescribes in addictions practice, cover seven elements:
| Element | Example for buprenorphine/naloxone |
|---|---|
| What it does and how | "It sits on the same receptor as fentanyl but only partly turns it on, which stops withdrawal and craving without the high." |
| What to expect and when | "Withdrawal should settle within an hour or two of the first dose. Craving usually drops over the first week." |
| How to take it | "Let the film dissolve under your tongue. Don't chew or swallow it. No food or drink for 15 minutes before or during." |
| Common adverse effects | Constipation, headache, sweating, dental problems from prolonged acidic contact — rinse with water after the film dissolves |
| Serious adverse effects and what to do | Respiratory depression when combined with sedatives or alcohol; precipitated withdrawal if taken too soon after a full agonist |
| Interactions | Benzodiazepines, alcohol, gabapentinoids, sedating antihistamines; CYP3A4 inhibitors and inducers |
| Missed dose and stopping | What to do about a missed dose, and the tolerance-loss warning below |
2. The Tolerance-Loss Teaching Point
This is the single most life-critical piece of education in opioid use disorder care and it is frequently omitted.
- Opioid tolerance falls rapidly after stopping methadone, buprenorphine, or after any period of abstinence — including incarceration, hospitalization, or residential treatment.
- A dose the patient used comfortably before treatment can be fatal after two weeks away from opioids.
- Overdose mortality is sharply elevated in the first two weeks after release from jail or prison and after discharge from residential treatment, precisely because of this mechanism.
- Teaching script: "If you stop this medicine and later use again, do not use the amount you used to use. Your body has lost its tolerance. Use less, use with someone, and have naloxone. This is the conversation I most need you to remember."
- Pair the teaching with a naloxone prescription at every transition, not only at initiation.
3. The Elements of Informed Consent
| Element | What must be established |
|---|---|
| Disclosure | Nature of the proposed treatment; material risks; expected benefits; reasonable alternatives; the option of no treatment and its consequences |
| Understanding | Confirmed by teach-back, not by signature |
| Capacity | The patient can communicate a choice, understand the information, appreciate how it applies to their own situation, and reason about the options |
| Voluntariness | Free of coercion. Court-mandated treatment complicates but does not eliminate voluntariness — the patient still consents to each specific intervention |
Intoxication does not automatically negate capacity, and withdrawal does not automatically negate it either — but both require assessment at the time of decision rather than assumption. Capacity is decision-specific: a patient may lack capacity to decline life-saving surgery while retaining capacity to choose between buprenorphine and methadone.
4. Informed Refusal
When a patient declines a recommended treatment, the process is the mirror image of consent and must be documented with equal care:
- Confirm the patient has capacity at the time of refusal.
- Disclose the specific, concrete consequences of declining — not a generic warning. "Without medication, your risk of dying from an overdose in the next year is several times higher" rather than "this is dangerous."
- Explore the reason. Most refusals reflect a correctable belief: a prior bad experience, stigma from a family member or mutual-help group, fear of "trading one drug for another," a cost or transportation barrier, or fear of losing custody.
- Offer alternatives, including a lower-intensity option the patient will accept.
- Leave the door open explicitly and document the invitation to return.
- Record the patient's own words, the consequences explained, and the alternatives offered.
5. Off-Label Prescribing Disclosure
Much of addictions pharmacotherapy is off-label: topiramate and gabapentin for alcohol use disorder, naltrexone plus bupropion for methamphetamine use disorder, gabapentin for cannabis withdrawal, naltrexone for gambling disorder. The disclosure standard:
- State plainly that the medication is not FDA-approved for this use.
- Describe the actual strength of the evidence, including the size of the expected benefit.
- Present alternatives, including approved treatments and non-pharmacological options.
- Document the conversation. "Off-label use discussed" is insufficient; record what was said about evidence and alternatives.
6. Common Medication-Teaching Errors in Addictions Care
| Error | Correction |
|---|---|
| Telling a patient on extended-release naltrexone they simply "cannot get high" | Teach that attempting to override the blockade with large opioid doses can be fatal, and that overdose risk rises sharply as the injection wears off |
| Failing to warn about precipitated withdrawal before buprenorphine induction | Teach the required interval since last full-agonist use and what precipitated withdrawal feels like, so the patient can report it immediately |
| Omitting dental care teaching with sublingual buprenorphine | Rinse with water after the film dissolves, delay brushing about an hour, maintain dental follow-up |
| Not discussing disulfiram's hidden alcohol sources | Mouthwash, cooking wine, some sauces, hand sanitizer, certain cold preparations; and that sensitivity persists up to 14 days after the last dose |
| Assuming a signed consent form equals informed consent | The form documents the process; teach-back demonstrates it |
A patient is completing a 90-day residential program and plans to stop buprenorphine at discharge. Which teaching point is most critical to prevent death?
A patient with severe opioid use disorder declines buprenorphine, saying she does not want to "trade one drug for another." She is alert, oriented and able to reason about her options. What constitutes appropriate informed refusal?
An APRN is starting topiramate off-label for alcohol use disorder. What must the informed consent discussion include beyond the usual risks and benefits?